Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
XON-7 by Xenothera for Metastatic Pancreatic Cancer: Likelihood of Approval
XON-7 is under clinical development by Xenothera and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase...
XON-7 by Xenothera for Sarcomas: Likelihood of Approval
XON-7 is under clinical development by Xenothera and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs...
XON-7 by Xenothera for Non-Small Cell Lung Cancer: Likelihood of Approval
XON-7 is under clinical development by Xenothera and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
XON-7 by Xenothera for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
XON-7 is under clinical development by Xenothera and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...
XON-7 by Xenothera for Metastatic Colorectal Cancer: Likelihood of Approval
XON-7 is under clinical development by Xenothera and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
XON-7 by Xenothera for Metastatic Ovarian Cancer: Likelihood of Approval
XON-7 is under clinical development by Xenothera and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData, Phase...
XON-7 by Xenothera for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
XON-7 is under clinical development by Xenothera and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...